India's Wockhardt launches drug in US market

Thursday, 21 June 2007, 07:00 Hrs
Printer Print Email Email
Mumbai: Indian pharma major Wockhardt Wednesday announced the launch of its antibiotic tablets Cefprozil in the US after receiving approval from the US Food and Drug Administration (US FDA).

Cefprozil, a Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections.

"Several of our products have seen a dramatic increase in the market share in the US over the last six months. Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million," Wockhardt chairman Habil Khorakiwala said in a statement.

The Cefprozil tablets, developed in-house, are manufactured at Wockhardt's US FDA certified formulation plant at Waluj in Maharashtra.

The $650 million firm has a market capitalisation of over $1 billion and has major presence in the markets of the US, Britain, Ireland, Germany and France. It employs over 7,000 professionals both in India and abroad.
Source: IANS
SPOTLIGHT
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..